| abstract |
A modulator of claspin (CLSPN) for use in the treatment of a cell proliferative disorder, preferably cancer, is disclosed. The cell proliferative disorder may also be associated with impaired BRCA function. The modulator may be an antibody against claspin or an RNA inhibitor or antisense oligomer, and may be used in conjunction with another antitumour agent. Purified inhibitors of claspin are also disclosed, and method of identifying such claspin modulators. |